HIV prevalence in Oman is low (<5 %); however, 45 % of the population are expatriates, including a portion originating from countries with high HIV prevalence (>5 %). HIV screening is performed at regional public health laboratories as part of a medical fitness programme for residency applicants. We conducted a retrospective evaluation of indeterminate serology results from 11 females of African origin, aged 21–43 years. Serology testing for HIV was conducted according to the national Oman algorithm: fourth-generation immunoassays (Bio-Rad GS HIV Combo Ag/Ab EIA, Siemens Enzygnost HIV Integral 4, Abbott ARCHITECT HIV Ag/Ab Combo, Roche Elecsys HIV Combi PT, bioMérieux VIDAS HIV DUO QUICK), confirmatory assays (Geenius HIV 1/2 Confirmatory, INNO-LIA HIV I/II Score) and PCR testing. Confirmatory testing to resolve indeterminate results was conducted with available samples for five patients using a combination of immunoassays, confirmatory assays, PCR/PERT and pro-viral DNA levels, at three external laboratories; Roche Diagnostics (Germany), Swiss National Laboratory (Switzerland) and Barts Health NHS Trust (UK). Nineteen serum, 15 plasma and two whole-blood samples were analysed. Nine of ten patients analysed on Bio-Rad and Siemens immunoassays were highly reactive; seven were highly reactive on the Abbott assay. Eight of nine patients tested with the Roche assay were negative. Three of four patients tested on the bioMérieux assay were negative. Five patients underwent confirmatory testing at external laboratories; all were negative by HIV-RNA or pro-viral DNA testing. In conclusion, HIV-RNA and pro-viral DNA testing is recommended for HIV screening of individuals from high-prevalence regions coming to low-prevalence regions.
World Health OrganizationService Delivery Approaches to HIV Testing and Counselling (HTC): A Strategic Policy Framework Geneva: World Health Organization; 2012
World Health OrganizationConsolidated Guidelines on HIV Testing Services: 5Cs: Consent, Confidentiality, Counselling, Correct Results and Connection 2015 Geneva: World Health Organization; 2015
EverettDB,
BaiselyKJ,
McNerneyR,
HambletonI,
ChirwaT et al. Association of schistosomiasis with false-positive HIV test results in an African adolescent population. J Clin Microbiol2010; 48:1570–1577 [View Article][PubMed]
VoroninY,
ZinsznerH,
KargC,
BrooksK,
CoombsR et al. HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physicians. Vaccine2015; 33:1243–1249 [View Article]
KimS,
LeeJ-H,
ChoiJY,
KimJM,
KimH-S.
False-positive rate of a "fourth-generation" HIV antigen/antibody combination assay in an area of low HIV prevalence. Clin Vaccine Immunol2010; 17:1642–1644 [View Article][PubMed]
LangR,
CharltonC,
BecktholdB,
KadivarK,
LavoieS et al. HIV misdiagnosis: a root cause analysis leading to improvements in HIV diagnosis and patient care. J Clin Virol2017; 96:84–88 [View Article][PubMed]
AvidorB,
ChemtobD,
TurnerD,
ZeldisI,
GirshengornS et al. Evaluation of the virtues and pitfalls in an HIV screening algorithm based on two fourth generation assays - A step towards an improved national algorithm. J Clin Virol2018; 106:18–22 [View Article][PubMed]
DelaneyKP,
BransonBM,
UniyalA,
PhillipsS,
CandalD et al. Evaluation of the performance characteristics of 6 rapid HIV antibody tests. Clin Infect Dis2011; 52:257–263 [View Article][PubMed]
MitchellEO,
StewartG,
BajzikO,
FerretM,
BentsenC et al. Performance comparison of the 4th generation Bio-Rad laboratories Gs HIV Combo Ag/Ab EIA on the EVOLIS automated system versus Abbott ARCHITECT HIV Ag/Ab Combo, Ortho anti-HIV 1+2 EIA on Vitros ECi and Siemens HIV-1/O/2 enhanced on Advia Centaur. J Clin Virol2013; 58:e79–e84 [View Article][PubMed]
KosackCS,
PageA-L,
BeelaertG,
BensonT,
SavaneA et al. Towards more accurate HIV testing in sub-Saharan Africa: a multi-site evaluation of HIV RDTs and risk factors for false positives. J Int AIDS Soc2017; 19:21345 [View Article][PubMed]